JP2018538000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538000A5 JP2018538000A5 JP2018533097A JP2018533097A JP2018538000A5 JP 2018538000 A5 JP2018538000 A5 JP 2018538000A5 JP 2018533097 A JP2018533097 A JP 2018533097A JP 2018533097 A JP2018533097 A JP 2018533097A JP 2018538000 A5 JP2018538000 A5 JP 2018538000A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- human
- recombinant
- seq
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003527 eukaryotic cell Anatomy 0.000 claims 20
- 238000000034 method Methods 0.000 claims 15
- 210000000349 chromosome Anatomy 0.000 claims 10
- 238000003776 cleavage reaction Methods 0.000 claims 10
- 230000007017 scission Effects 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000002459 blastocyst Anatomy 0.000 claims 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000013607 AAV vector Substances 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000006780 non-homologous end joining Effects 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021031458A JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387318P | 2015-12-23 | 2015-12-23 | |
| US62/387,318 | 2015-12-23 | ||
| US201662416513P | 2016-11-02 | 2016-11-02 | |
| US62/416,513 | 2016-11-02 | ||
| PCT/US2016/068289 WO2017112859A1 (en) | 2015-12-23 | 2016-12-22 | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031458A Division JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538000A JP2018538000A (ja) | 2018-12-27 |
| JP2018538000A5 true JP2018538000A5 (enExample) | 2020-02-06 |
| JP6846429B2 JP6846429B2 (ja) | 2021-03-24 |
Family
ID=57794384
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533097A Active JP6846429B2 (ja) | 2015-12-23 | 2016-12-22 | ヒトβ−２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2021031458A Active JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A Pending JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031458A Active JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A Pending JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20190017075A1 (enExample) |
| EP (2) | EP3394253B1 (enExample) |
| JP (3) | JP6846429B2 (enExample) |
| AU (2) | AU2016379393B2 (enExample) |
| CA (1) | CA3009637A1 (enExample) |
| ES (1) | ES2901000T3 (enExample) |
| WO (1) | WO2017112859A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4108255A1 (en) | 2015-10-05 | 2022-12-28 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| AU2016333886B2 (en) | 2015-10-05 | 2020-10-08 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| CA3009637A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018208837A1 (en) * | 2017-05-08 | 2018-11-15 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| MY201573A (en) | 2017-05-12 | 2024-03-02 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| AU2018292526A1 (en) | 2017-06-30 | 2020-01-16 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
| TW201923073A (zh) * | 2017-11-20 | 2019-06-16 | 新加坡商泰莎治療私人有限公司 | 經修飾之k562細胞 |
| US20190175651A1 (en) * | 2017-12-13 | 2019-06-13 | Janssen Biotech, Inc. | Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression |
| WO2019200122A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| JP7542441B2 (ja) | 2018-05-11 | 2024-08-30 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 癌を治療するための方法及び組成物 |
| US20220119786A1 (en) * | 2019-01-10 | 2022-04-21 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified transferrin gene |
| CN116200342A (zh) | 2019-04-03 | 2023-06-02 | 精密生物科学公司 | 包含microRNA适应的shRNA（shRNAmiR）的遗传修饰的免疫细胞 |
| WO2020206231A1 (en) | 2019-04-05 | 2020-10-08 | Precision Biosciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| US20220195407A1 (en) | 2019-05-07 | 2022-06-23 | Precision Biosciences, Inc. | Optimization of engineered meganucleases for recognition sequences |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| CA3172292A1 (en) * | 2020-08-21 | 2022-02-24 | Cassandra GORSUCH | Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene |
| KR20230123925A (ko) * | 2020-09-29 | 2023-08-24 | 뉴엑셀 테라퓨틱스 아이엔씨. | Neurod1 및 dlx2 벡터 |
| JP2023543362A (ja) * | 2020-09-29 | 2023-10-13 | ニューエクセル・セラピューティクス・インコーポレイテッド | Ｎｅｕｒｏｄ１組み合わせベクター |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| EP4419660A2 (en) * | 2021-10-19 | 2024-08-28 | Precision BioSciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| ES2626025T3 (es) | 2005-10-18 | 2017-07-21 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| WO2010015899A2 (en) * | 2008-08-04 | 2010-02-11 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| EP2660317B1 (en) | 2007-10-31 | 2016-04-06 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| DK3489366T3 (da) | 2011-06-01 | 2020-02-24 | Prec Biosciences Inc | Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener |
| ES2782125T3 (es) * | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| CA3009637A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
-
2016
- 2016-12-22 CA CA3009637A patent/CA3009637A1/en active Pending
- 2016-12-22 US US16/065,756 patent/US20190017075A1/en not_active Abandoned
- 2016-12-22 WO PCT/US2016/068289 patent/WO2017112859A1/en not_active Ceased
- 2016-12-22 EP EP16825979.4A patent/EP3394253B1/en active Active
- 2016-12-22 ES ES16825979T patent/ES2901000T3/es active Active
- 2016-12-22 AU AU2016379393A patent/AU2016379393B2/en active Active
- 2016-12-22 JP JP2018533097A patent/JP6846429B2/ja active Active
- 2016-12-22 EP EP21193857.6A patent/EP3988655A3/en not_active Withdrawn
-
2020
- 2020-10-19 US US17/074,135 patent/US20210032664A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021031458A patent/JP7203873B2/ja active Active
-
2022
- 2022-12-27 JP JP2022209145A patent/JP2023052095A/ja active Pending
-
2023
- 2023-04-03 AU AU2023202035A patent/AU2023202035A1/en not_active Abandoned
- 2023-10-20 US US18/491,484 patent/US20240052373A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538000A5 (enExample) | ||
| US10858662B2 (en) | Genome editing with split Cas9 expressed from two vectors | |
| US20210301301A1 (en) | Targeted modification of rat genome | |
| ES2784754T3 (es) | Métodos y composiciones para modificar un locus objetivo | |
| IL277883B1 (en) | Optimized engineered nucleases with specificity for the human t-cell receptor alpha constant region gene | |
| JP2018536390A5 (enExample) | ||
| CN104364380B (zh) | 核酸酶介导的使用大靶向载体的靶向 | |
| NZ773169A (en) | Universal donor cells | |
| JP2017018125A5 (enExample) | ||
| JP2021502085A5 (enExample) | ||
| Mizuno-Iijima et al. | Efficient production of large deletion and gene fragment knock-in mice mediated by genome editing with Cas9-mouse Cdt1 in mouse zygotes | |
| JP2016504026A5 (enExample) | ||
| IL274179B2 (en) | Targeted replacement of endogenous T cell receptors | |
| NZ705675A (en) | Engineered transgene integration platform (etip) for gene targeting and trait stacking | |
| JP2016165307A5 (enExample) | ||
| JP2017513479A5 (enExample) | ||
| JP2012522501A5 (enExample) | ||
| IL309801A (en) | Use of protein domains interacting with the nucleosome to enhance targeted genome modification | |
| JP2020505025A5 (enExample) | ||
| CN108690845A (zh) | 基因组编辑系统和方法 | |
| JP2017538401A5 (enExample) | ||
| JP2018535663A5 (enExample) | ||
| JP2018531624A5 (enExample) | ||
| JP2018525979A5 (enExample) | ||
| HRP20201443T1 (hr) | Postupci i pripravci za liječenje genetskog stanja |